AI assistant
DEXCOM INC — Director's Dealing 2022
Mar 14, 2022
30198_dirs_2022-03-14_f9039a3d-81dc-410b-a721-4efe877854ee.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-03-10
Reporting Person: Patterson Chad (EVP, Global Marketing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-03-10 | Common Stock | S | 776 | $401.27 | Disposed | 15228 | Direct |
Footnotes
F1: On June 14, 2021, Mr. Patterson adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Patterson. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Included in this number are 13,675 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,756 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,697 of which were granted on March 8, 2020 and shall vest through March 8, 2023.